SCHEMBL6292391

SCHEMBL6292391

O=C(O)Nc1ccc2c(c1)COCC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIR O00625 1/20 0.47
NPC1 O15118 12/20 0.45
RAB9A P51151 12/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
SMN1; SMN2 Q16637 5/20 0.44
NFKB1 P19838 3/20 0.44
NFKB2 Q00653 3/20 0.44
RELA Q04206 3/20 0.44
TP53 P04637 3/20 0.44
HTT P42858 3/20 0.44
POLB P06746 2/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
HPGD P15428 3/20 0.43
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
PKM P14618 2/20 0.43
ALOX15 P16050 1/20 0.42
STAT1 P42224 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6291312 0.94 NPC1 (0.45) PIRNPC1RAB9AKMT2AMEN1
SCHEMBL30494024 0.78 NPC1 (0.65) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL11896022 0.78 NPC1 (0.70) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL21894537 0.76 BTK (0.38) PIRNPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL16711720 0.75 CA12 (0.56) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL5286604 0.75 ALDH1A1 (0.59) PIRKMT2AMEN1POLBGAA
SCHEMBL30539307 0.75 ALDH1A1 (0.59) PIRKMT2AMEN1POLBGAA
SCHEMBL26633281 0.74 FBP1 (0.36) PIRNPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL6291401 0.73 NPC1 (0.55) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL5018064 0.72 RAB9A (0.49) NPC1RAB9AKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972286-B2 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle PHARMACIA AND UPJOHN COMPANY (US) 2005-12-06 US disclosed
US-20040186293-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle JOHNSON PAUL D (US) 2004-09-23 US disclosed
US-20040176609-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle JOHNSON PAUL D (US) 2004-09-09 US disclosed
EP-1337530-A1 OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS Pharmacia & Upjohn Company (US) 2003-08-27 EP disclosed
US-20020133021-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle PHARMACIA & UPJOHN COMPANY 2002-09-19 US disclosed
WO-2002059115-A1 OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020133021-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle OXA1L, CDK16, MT-ND6 PIR 588/4885NPC1 3443/4885RAB9A 3115/4885
US-20040186293-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle OXA1L, CDK16, MT-ND6 PIR 588/4885NPC1 3443/4885RAB9A 3115/4885
US-20040176609-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle OXA1L, CDK16, MT-ND6 PIR 588/4885NPC1 3443/4885RAB9A 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.